Therapeutic immunization with a glatiramer acetate derivative does not alter survival in G93A and G37R SOD1 mouse models of familial ALS

Neurobiology of Disease

Volumn 26, Issue 1, 2007, Pages 146-152

  Haenggeli, Christine ^a   Julien, Jean Pierre ^b   Lee Mosley, R ^c   Perez, Natalie ^a   Dhar, Alok ^c   Gendelman, Howard E ^c   Rothstein, Jeffrey D ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITÉ LAVAL   (Canada)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

ALS; Disease progression; Glatiramer acetate; Immunization; SOD1; TV 5010

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; GLATIRAMER; TV 5010; UNCLASSIFIED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG INDICATION; DRUG RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MOUSE; MOUSE MUTANT; MOUSE STRAIN; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; TRANSGENIC MOUSE;

AGING; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; BODY WEIGHT; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; IMMUNIZATION; MICE; MICE, TRANSGENIC; MUSCULOSKELETAL EQUILIBRIUM; NEUROPROTECTIVE AGENTS; PEPTIDES; PSYCHOMOTOR PERFORMANCE; SUPEROXIDE DISMUTASE; SURVIVAL ANALYSIS;

EID: 33947216452     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2006.12.013     Document Type: Article

References (29)

1. Aharoni R., et al. Neurogenesis and neuroprotection induced by peripheral immunomodulatory treatment of experimental autoimmune encephalomyelitis. J. Neurosci. 25 (2005) 8217-8228
2. Aharoni R., et al. The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 19045-19050
3. Aharoni R., et al. Immunomodulatory therapeutic effect of glatiramer acetate on several murine models of inflammatory bowel disease. J. Pharmacol. Exp. Ther. 318 (2006) 68-78
4. Almer G., Vukosavic S., Romero N., and Przedborski S. Inducible nitric oxide synthase up-regulation in a transgenic mouse model of familial amyotrophic lateral sclerosis. J. Neurochem. 72 (1999) 2415-2425
5. Almer G., et al. Increased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis. Ann. Neurol. 49 (2001) 176-185
6. Angelov D.N., et al. Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 4790-4795
7. Barbeito L.H., et al. A role for astrocytes in motor neuron loss in amyotrophic lateral sclerosis. Brain Res. Brain Res Rev. 47 (2004) 263-274
8. Benner E.J., et al. Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 9435-9440
9. Ben Younes-Chennoufi A., Rozier A., Dib M., Bouche P., Lacomblez L., Mombo N., Ben Simon G., Yu R.K., Baumann N., and Meininger V. Anti-sulfoglucuronyl paragloboside IgM antibodies in amyotrophic lateral sclerosis. J. Neuroimmunol. 57 (1995) 111-115
10. Blair M., et al. Effect of glatiramer acetate on primary and secondary degeneration of retinal ganglion cells in the rat. Invest. Ophthalmol. Visual Sci. 46 (2005) 884-890
11. Boska M.D., et al. Quantitative 1H magnetic resonance spectroscopic imaging determines therapeutic immunization efficacy in an animal model of Parkinson's disease. J. Neurosci. 25 (2005) 1691-1700
12. Bruijn L.I., et al. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu. Rev. Neurosci. 27 (2004) 723-749
13. Butovsky O., et al. Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 11784-11789
14. Cleveland D.W., and Rothstein J.D. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat. Rev., Neurosci. 2 (2001) 806
15. Drachman D.B., Frank K., Dykes-Hoberg M., Teismann P., Almer G., Przedborski S., and Rothstein J.D. Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann. Neurol. 52 (2002) 771-778
16. Frenkel D., et al. Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease. J. Clin. Invest. 115 (2005) 2423-2433
17. Gordon P.H., et al. Randomized controlled phase II trial of glatiramer acetate in ALS. Neurology 66 (2006) 1117-1119
18. Gurney M.E., Liu R., Althaus J.S., Hall E.D., and Becker D.A. Mutant mice, Cu,Zn superoxide dismutase, and motor neuron degeneration. Science 266 (2002) 1587
19. Julien J.P., and Kriz J. Transgenic mouse models of amyotrophic lateral sclerosis. Biochim. Biophys. Acta 1762 (2006) 1013-1024
20. Kriz J., et al. Efficient three-drug cocktail for disease induced by mutant superoxide dismutase. Ann. Neurol. 53 (2003) 429
21. McGeer P.L., and McGeer E.G. Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve 26 (2002) 459-470
22. McGeer E.G., and McGeer P.L. Pharmacologic approaches to the treatment of amyotrophic lateral sclerosis. BioDrugs 19 (2005) 31-37
23. Neuhaus O., et al. Putative mechanisms of action of statins in multiple sclerosis-Comparison to interferon-beta and glatiramer acetate. J. Neurol. Sci. 233 (2005) 173-177
24. Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp E., Hentati A., Donaldson D., Goto J., O'Reagan J.P., and Deng H.X. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362 (1993) 59-62
25. Sargsyan S.A., et al. Microglia as potential contributors to motor neuron injury in amyotrophic lateral sclerosis. Glia 51 (2005) 241-253
26. Schori H., et al. Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 3398-3403
27. Stephenson D., et al. Cytosolic phospholipase A2 is induced in reactive glia following different forms of neurodegeneration. Glia 27 (1999) 110-128
28. Wolinsky J.S. The use of glatiramer acetate in the treatment of multiple sclerosis. Adv. Neurol. 98 (2006) 273-292
29. Wong P.C., Pardo C.A., Borchelt D.R., Lee M.K., Copeland N.G., Jenkins N.A., Sisodia S.S., Cleveland D.W., and Price D.L. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 14 (1995) 1105-1116